0 CHECKOUT

Romania Pharmaceutical Report - Q1, 2015

  • ID: 3260515
  • June 2015
  • Region: Romania
  • 11 Pages
  • Emerging Markets Direct
1 of 3
In the 12 months ending March 2015, the pharmaceutical market value increased by 10% y/y to RON12.6bn

This report covers the market developments in Q1/2015 and the data available as of May 2015.

The pharmaceutical sales performed above market expectations and increased at double-digit annual pace in Q1/2014 in RON and EUR terms, after having risen by 11.8% y/y in the previous quarter (up by 9.7% y/y in EUR terms). Sales of OTC drugs surged by 27.7% y/y to RON0.6bn, while the hospital segment amounted to RON0.4bn, up by 11.5% y/y.

In the 12 months ending March 2015, the pharmaceutical market value increased by 10% y/y to RON12.6bn. The Rx segment advanced by 7.4% y/y in RON terms, while the OTC and hospital sales increased by 20.6% y/y and 11.7% y/y respectively.

The performance of the Romanian pharmaceutical market is influenced by a broad variety of factors, among which the most important are related to regulatory measures and public spending. Accordingly, the announced medicine price cuts might drive downwards the pharmaceutical sales value this year, to minus 2.8% y/y in local currency terms, according to market data. In terms of actual demand, however, considering the aging population, there is enough room for growth. Our QuERi database forecasts show that the demand for treatment will continue increasing in 2015-2017.

Key points:

- Pharmaceutical sales rise y/y in EUR, RON terms in Q1/2015
- Medicine price cut expected to drive downwards pharma market value in 2015
- Pharmaceutical imports, exports decline in 2014
- Antibiotice Iasi seeks investors for building new production capacities
- Biofarm plans acquisition of local peer
- Polisano to sell 25% stake to investment fund for €30mn
- Dona pharmacy chain launches online store

Note: Product cover images may vary from those shown
2 of 3

Executive summary
Market overview
Pharmaceutical sales rise y/y in EUR, RON terms in Q1/2015
Medicine price cut expected to drive downwards pharma market value in 2015
Sanofi tops pharma companies ranking in 12 months ending March 2015
Pharmaceutical imports, exports decline in 2014
Production of medicines inches up 1.5% y/y in Q1/2015
Producers
Domestic pharmaceutical producers focus on exports, developing OTC portfolio
Antibiotice Iasi seeks investors for building new production capacities
Zentiva reports higher revenues, lower profit in Q1/2015
Gedeon Richter’s sales in Romania down y/y in Q1/2015
Biofarm plans acquisition of local peer
Distribution & Retail
Polisano to sell 25% stake to investment fund for €30mn
Farmaceutica Remedia expects higher revenues, profit this year
Dona pharmacy chain launches online store
A&D Pharma moves on with expansion of Punkt chain
Ropharma plans investments in pharmacy chain expansion this year

List of Tables:
Table 1 Pharmaceutical production in 2011-2015 (monthly, y/y)
Table 2 Antibiotice SA- Selected financials in 2013-2015 (RON, y/y)
Table 3 Zentiva SA- Selected financials in 2013-2015 (RON, y/y)
Table 4 Biofarm SA- Selected financials in 2013-2015 (RON, y/y)
Table 5 Farmaceutica Remedia SA- Selected financials in 2013-2015 (RON, y/y)
Table 6 Ropharma S.A.- Selected financials in 2013-2015 (RON, y/y)

List of Figures:
Figure 1 Pharma quarterly sales in 2006-2015 (€mn, PPP)
Figure 2 Pharmaceutical market demand in 2007-2017f (annual, $mn)
Figure 3 Top 10 pharma companies by revenues in 12 months ending March 2015 (RONmn)
Figure 4 Pharmaceutical products foreign trade in 2003-2014 (monthly, €mn)
Figure 5 Pharmaceutical product manufacturing-Foreign trade in 2007-2017f ($mn)
Figure 6 Pharmaceutical manufacturing index in 2011-2015 (monthly, 2010=100, unadjusted)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.